By partnering with Epic Aura, NeoGenomics delivers genomic testing that fits naturally into Epic workflows, eliminating unnecessary manual steps and reducing errors tied to transcription and re‑entry. 🔗 neogenomics.com/providers/cl…

Looking for deeper insights to support your oncology program? Visit us at #ESMO2026 to learn how our Pharma Services and Oncology Data Solutions teams help biopharma organizations accelerate therapeutic development. 📍 Booth 8028 📅 October 23-27 🔗 mailchi.mp/neogenomics/esmo2…

#NeoGenomics has expanded its partnership with Indica Labs, a global leader in AI-powered digital pathology: ir.neogenomics.com/news-even….

#BreastCancerAwarenessMonth is an important time to highlight tools supporting better #PatientCare. RaDaR® ST, which is specifically indicated for use in #BreastCancer (neogenomics.com/providers/on…®st-mrd), is designed to support confidence across the cancer continuum of care.

Warren Stone, #NeoGenomics' current President and COO, has been appointed CEO and a member of the Board, effective January 4, 2027. ​ Tony Zook, current CEO and member of the Board, will transition to Executive Chair on January 4, 2027.

#BreastCancerAwarenessMonth begins today🎗️ All month long, we will be sharing education and resources, highlighting our testing solutions, and more. #BreastCancerAwarenessMonth #BreastCancerAwareness2025 #CancerTesting #Oncology #NeoGenomics

Learning, growing, and leading together. 💙💚 Recently, leaders from across the organization came together at our HQ in Fort Myers, FL, for hands-on learning focused on business acumen and change resiliency. #WorkAtNeo #NeoSPIRIT #LifeAtNeo

RaDaR® ST provides clear, actionable answers: neogenomics.com/providers/on…. #NeoGenomics #RaDaRST #PrecisionOncology #MRD

RaDaR® ST helps pharma partners identify high-risk, ctDNA-positive patients, enriching your trial population for better outcomes. See how to stratify smarter with RaDaR ST: neogenomics.com/partners/bio….

Predict cancer’s recurrence with RaDaR® ST. It detects molecular residual disease with high sensitivity, helping forecast disease progression before clinical symptoms arise. 🔗 Learn more about RaDaR® ST for Pharma Partners: neogenomics.com/partners/bio….

Claudin 18.2 (CLDN18.2) is an actionable target for patients with advanced or metastatic gastric (GEJ) adenocarcinoma. Learn more about 18 FDA (VYLOY®) for Gastric/GEJ Adenocarcinoma: neogenomics.com/providers/te….

Today, we pause to remember those whose lives were lost and to honor the first responders, military members, and all those who showed extraordinary courage to save others on September 11, 2001. #PatriotDay

Biomarker-informed decision-making is transforming lung cancer care. c-MET CDx for NSCLC IHC testing (neogenomics.com/providers/te…) identifies NSCLC patients eligible for a new FDA-approved targeted therapy, offering new personalized treatment opportunities.

Get DNA and RNA alterations in a single test for a complete genomic view with Neo Comprehensive® – Myeloid Disorders: neogenomics.com/providers/te….

Happy Labor Day! #LaborDay #LaborDay2026

PTEN IHC CDx is now available as part of PanTracer Pro, pairing IHC-based PTEN deficiency identification with comprehensive genomic profiling for a more complete biomarker picture. Learn more: neogenomics.com/providers/te…. #ProstateCarcinoma #Oncology #ComprehensiveGenomicProfiling

Wearing green for #MentalHealthAwareness 💚 At #NeoGenomics, we believe supporting mental health and well-being is just as important as supporting physical health. If you're interested in an organization committed to supporting emotional well-being, visit jobs.jobvite.com/neogenomics.

See the impact of diverse population data: neogenomics.com/oncology-dat…. Tap into a dataset representing the entire U.S. population—over 3M patient profiles from 4,400 healthcare organizations.

Paletrra offers advanced spatial analytics aligned to your exact specifications. Gain deeper insights into the tumor microenvironment: neogenomics.com/paletrratm

As the NSCLC treatment landscape evolves, actionable biomarkers like c‑MET play an increasingly critical role. The c‑MET CDx for NSCLC IHC supports precision‑driven testing to guide targeted therapy decisions: neogenomics.com/providers/te… #NeoGenomics #NSCLC #PrecisionMedicine #cMET